North America Multiple Sclerosis Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce)

No. of Pages: 130    |    Report Code: TIPRE00022633    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Multiple Sclerosis Therapeutics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Multiple Sclerosis Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Multiple Sclerosis Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Increase in multiple sclerosis diagnosis
  • 5.1.2 Rising demand for effective MS therapeutics
5.2 Market Opportunities
  • 5.2.1 Expansion in neurodegenerative disease therapeutics
  • 5.2.2 Rising opportunities in MS drug development
5.3 Future Trends
  • 5.3.1 Personalized therapies for multiple sclerosis
  • 5.3.2 Rise in biologic drug usage for MS treatment
5.4 Impact of Drivers and Restraints

6. North America Multiple Sclerosis Therapeutics Market Regional Analysis

6.1 North America Multiple Sclerosis Therapeutics Market Overview
6.2 North America Multiple Sclerosis Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 North America Multiple Sclerosis Therapeutics Market Forecast Analysis

7. North America Multiple Sclerosis Therapeutics Market Analysis – by Drug Class

7.1 Immunosuppressant
  • 7.1.1 Overview
  • 7.1.2 Immunosuppressant: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Immunomodulators
  • 7.2.1 Overview
  • 7.2.2 Immunomodulators: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Multiple Sclerosis Therapeutics Market Analysis – by Route of Administration

8.1 Injectable
  • 8.1.1 Overview
  • 8.1.2 Injectable: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Oral
  • 8.2.1 Overview
  • 8.2.2 Oral: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9. North America Multiple Sclerosis Therapeutics Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Oral: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Retail Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Oral: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.3 E-Commerce
  • 9.3.1 Overview
  • 9.3.2 Oral: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10. North America Multiple Sclerosis Therapeutics Market – North America Analysis

10.1 North America
  • 10.1.1 North America Multiple Sclerosis Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
  • 10.1.1.1 North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.1.1 US: North America Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
    • 10.1.1.1.2 US: North America Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
    • 10.1.1.1.3 US: North America Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.2 Canada: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.2.1 Canada: North America Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
    • 10.1.1.2.2 Canada: North America Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
    • 10.1.1.2.3 Canada: North America Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.3 Mexico : North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
    • 10.1.1.3.2 Mexico : North America Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
    • 10.1.1.3.3 Mexico : North America Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Multiple Sclerosis Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Merck & Co., Inc.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Novartis AG
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Bayer AG
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Sanofi
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Horizon Therapeutics plc
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Takeda Pharmaceutical Company Limited
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 F. HOFFMANN-LA ROCHE LTD
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Biogen
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - N Market

  1. Merck & Co., Inc.
  2. Novartis AG
  3. Bayer AG
  4. Sanofi
  5. Bristol-Myers Squibb Company
  6. Horizon Therapeutics plc
  7. TEVA PHARMACEUTICAL INDUSTRIES LTD
  8. Takeda Pharmaceutical Company Limited
  9. F. HOFFMANN-LA ROCHE LTD
  10. Biogen
north-america-multiple-sclerosis-therapeutics-market